European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE

THALEA II - Telemonitoring and Telemedicine for Hospitals Assisted by ICT for Life saving co-morbid patients in Europe As part of a Patient personalised care program of the EU

Periodic Reporting for period 2 - THALEA II (THALEA II - Telemonitoring and Telemedicine for Hospitals Assisted by ICT for Life saving co-morbid patients in Europe As part of a Patient personalised care program of the EU)

Período documentado: 2020-12-01 hasta 2021-06-30

In the upcoming 20 years, the European society is facing an enormous imbalance and possible collaps of the social system due to ongoing demographic changes. The proportion of the agening population will drastically increase, while the number of young people as for instance graduates will decrease. Hence, more patients will be in need for treatment, resulting in rising costs for the healthcare sector. On the other hand, less caregivers, especially professionals and intensive care specialists will be available to treat the tremendous amout of patients. In addition, irrespective of private or public insurance systems, potential income or financial volume for healthcare systems will decline as the net-payers will supply net-consumers. Hence, healthcare systems are urgently in need of sound solutions to answer this threat.

Telemedicine has the ability to offer a solution to the aforementioned problems. By use of a telemedical approach on intensive care units (ICUs), patients will benefit from a consistently high quality of care, irrespective of where they live (rural vs. urban area). In addition, efficiency and safety outcomes with a reduction of ICU length of stay of 20-50 % can be achieved by the use of telemedicine and will consequently combat a lack of ICU beds.

THALEA II is the first ICT public procurement of innovative solutions (PPI), emerging from THALEA, a pre-commercial procurement (PCP) in the healthcare sector, serving a common demand in Intensive Care Medicine. It aims for purchase and implementation of a manufacturer independent solution for telemedicine in ICU. Through the implementation of THALEA solution, telemedicine on ICU care programs will be more effective and personalized solutions will be feasible. Furthermore, telemedicine application has the ability to streamline healthcare delivery processes, improve cost-efficiency while maintaining or improving patient safety.
The THALEA II project has two main objectives. Firstly, a radical new telemedicine system is purchased, meeting the identified need of ICU within telemedicine of the eHealth sector through innovative ICT solutions. Secondly, the THALEA PPI process, including its advantages and results, acts as pilot project for eHealth.
THALEA II is a procurement project, funded under h2020 programme, which aims at procuring a certified, manufacturer independent software solution for intensive care medicine. It serves as a second security layer for medical specialists on the ward. This will improve patient safety and outcome of treatment. To realize the purchase of such an advanced software solution, certain developments and tasks had to be fulfilled during the course of THALEA II.

The project started in June 2016 with a consortium of five entities including three procurers. Due to the fact that THALEA II is a procurement project, the procurement departments and also legal departments had to be involved from day one. The call for tender documents are the central element of this project. Those documents include a "request for tender" document, a functional specification matrix, several procurement documents related to German procurement processes (lead procurer UKA, therefore German procurement law is applicable). Those documents had to be developed and finalized during the project.
Furthermore, dissemination and exploitation of project progress and results was one aim of THALEA II. Therefore, a project website had to be set up and maintained during project activities. Dissemination activities including a newsletter, regularly updating the project website, and involvement on fairs and congresses were also part of project work during the first project period. One extraordinary example for a dissemination activity held during the course of THALEA II was the presentation of THALEA on the digital summit 2017. Professor Gernot Marx presented the THALEA prototype to the German chancellor Dr Angela Merkel, who was very impressed by such a device and eager to see it in real life settings.

THALEA II as procurement project strives to maximize market impact by including as many procurers as possible, who identified the need of such a specific software solution for intensive care medicine. As a result, THALEA II consortium tried to increase their buyers group by searching for potential partners. This was executed by participation in congresses as well as participation on fairs, like the MEDICA. There were several interested parties during the search process, which led in the end to one additional procuring partner from Vienna, Austria. In addition, THALEA consortium wanted to stay informed on recent developments in the sector of intensive care medicine and data extraction software solutions. Therefore, an open market consultation (OMC) had been performed. Due to the fact that THALEA II is an active procurement project, the OMC was performed as an online questionnaire, in order to prevent market agreements, respecting transparency and equality as leading principles in the procurement process.
One of the most crucial elements of a purchasable THALEA II solution is a certification as medical device, which makes it possible to use the product in daily care practices. This process took the industry longer than expected, which led to a shift in timing with respect to the call for tender. However, a sound time line for the call for tender, as well as the following deployment and evaluation phase could be developed. Finalization of call for tender documents, joint procurement agreement and open market consultation could be realized during the first project period.
Before start of THALEA and THALEA II there was no manufacturer independent software solution present for intensive care medicine, which could extract data from existing source systems and display the data in a "cockpit" to a clinical expert. THALEA closed this gap and led to development of such a software, which enables an intensive care specialist in a telemedical centre to support colleagues on the ward and detect deterioration of patients earlier than it would have been the case before.
After deployment of THALEA solution in hospitals it is expected that deterioration as well as length of stay and death will improve for intensive care patients. Consequently, hospitals and society will benefit from positive socio-economic impacts and reduction of intensive care medicine costs.